C4 Therapeutics: Funding, Investors & Team (Oct 2026)
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.
C4 Therapeutics has raised $150M across 1 funding round on record, the most recent an undisclosed round of $150M announced in Jun 2020.
That round is above the $4.9M median round size for Health Care companies tracked on FundedIQ over the last two years.
C4 Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2020.
C4 Therapeutics Funding Rounds
C4 Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
C4 Therapeutics Funding Compared to Other Health Care Startups
C4 Therapeutics' latest round of $150M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like C4 Therapeutics in Health Care and Cambridge
Companies Similar to C4 Therapeutics
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…
SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…
Aptatek is developing cutting edge technologies for portable disease management devices that will improve…
Flow Medical offers multi-function catheters to aid in the diagnosis and treatment of venous thromboembolic…
Light Wave Dental Management offers management services for high-quality dental offices in Virginia.…
For health care systems and payers focused on improving maternal outcomes and health equity, our product is a…
Tempo Therapeutics creates materials that are designed for regenerative medicine, with a focus on being…
Vibronix was established by Dr. Ji-Xin Cheng and Dr. Pu Wang at Purdue University with the goal of offering…
People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…
C4 Therapeutics Funding FAQs
What does C4 Therapeutics do?
C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.
How much funding has C4 Therapeutics raised?
C4 Therapeutics has raised $150M across 1 round on record. The most recent is an undisclosed round of $150M announced in Jun 2020.
When did C4 Therapeutics last raise funding?
C4 Therapeutics' most recent funding round on record is an undisclosed round of $150M, announced in Jun 2020.
Who is the CEO of C4 Therapeutics?
Andrew Phillips is listed as CEO at C4 Therapeutics.
Where is C4 Therapeutics headquartered?
C4 Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does C4 Therapeutics have?
C4 Therapeutics is in the 101-250 employee band.
How does C4 Therapeutics' funding compare to other Health Care startups?
C4 Therapeutics' latest round of $150M is above the $4.9M median round size for Health Care companies on FundedIQ across 3,659 tracked companies over the last two years.
About FundedIQ's C4 Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for C4 Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.